115 results on '"Scarselli, Elisa"'
Search Results
2. Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy
- Author
-
D’Alise, Anna Morena and Scarselli, Elisa
- Published
- 2023
- Full Text
- View/download PDF
3. Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.
- Author
-
Bartolomeo, Rosa, Troise, Fulvia, Allocca, Simona, Sdruscia, Giulia, Vitale, Rosa, Bignone, Veronica, Petrone, Anna Maria, Romano, Giuseppina, D'Alise, Anna Morena, Ruzza, Valentino, Garzia, Irene, Leoni, Guido, Merone, Rossella, Lanzaro, Francesca, Colloca, Stefano, Siani, Loredana, Scarselli, Elisa, and Cotugno, Gabriella
- Subjects
DNA vaccines ,CANCER vaccines ,GENETIC vectors ,VACCINE trials ,PEPTIDES ,VIRAL shedding - Abstract
Quality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer vaccine based on heterologous prime/boost administration of two multivalent viral vector products: GAd-209 and MVA-209. These consist of a mix of four Adeno (Great Ape Adenovirus; GAd) and four Modified Vaccinia Ankara (MVA) vectors respectively, each containing a different transgene encoding a synthetic polypeptide composed of antigenic peptide fragments joined one after the other. The potency assay employs quantitative Reverse Transcription PCR (RT-Q-PCR) to quantitatively measure the transcripts from the four transgenes encoded by each product in in vitro infected cells, enabling simultaneous detection. Results showcase the assay's robustness and biological relevance, as it effectively detects potency loss in one component of the mixture comparably to in vivo immunogenicity testing. This report details the assay's setup and validation, offering valuable insights for the clinical development of similar genetic vaccines, particularly those encoding synthetic polypeptides. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis
- Author
-
Sasso, Emanuele, Froechlich, Guendalina, Cotugno, Gabriella, D’Alise, Anna Morena, Gentile, Chiara, Bignone, Veronica, De Lucia, Maria, Petrovic, Biljana, Campadelli-Fiume, Gabriella, Scarselli, Elisa, Nicosia, Alfredo, and Zambrano, Nicola
- Published
- 2020
- Full Text
- View/download PDF
5. Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer.
- Author
-
Seclì, Laura, Leoni, Guido, Ruzza, Valentino, Siani, Loredana, Cotugno, Gabriella, Scarselli, Elisa, and D'Alise, Anna Morena
- Subjects
GENETIC vectors ,CANCER vaccines ,VIRAL vaccines ,ANTINEOPLASTIC agents ,TECHNOLOGICAL innovations - Abstract
The aim of personalized cancer vaccines is to elicit potent and tumor-specific immune responses against neoantigens specific to each patient and to establish durable immunity, while minimizing the adverse events. Over recent years, there has been a renewed interest in personalized cancer vaccines, primarily due to the advancement of innovative technologies for the identification of neoantigens and novel vaccine delivery platforms. Here, we review the emerging field of personalized cancer vaccination, with a focus on the use of viral vectors as a vaccine platform. The recent advancements in viral vector technology have led to the development of efficient production processes, positioning personalized viral vaccines as one of the preferred technologies. Many clinical trials have shown the feasibility, safety, immunogenicity and, more recently, preliminary evidence of the anti-tumor activity of personalized vaccination, fostering active research in the field, including further clinical trials for different tumor types and in different clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
- Author
-
Passariello, Margherita, D’Alise, Anna Morena, Esposito, Annachiara, Vetrei, Cinzia, Froechlich, Guendalina, Scarselli, Elisa, Nicosia, Alfredo, and De Lorenzo, Claudia
- Published
- 2019
- Full Text
- View/download PDF
7. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
- Author
-
D’Alise, Anna Morena, Leoni, Guido, Cotugno, Gabriella, Troise, Fulvia, Langone, Francesca, Fichera, Imma, De Lucia, Maria, Avalle, Lidia, Vitale, Rosa, Leuzzi, Adriano, Bignone, Veronica, Di Matteo, Elena, Tucci, Fabio Giovanni, Poli, Valeria, Lahm, Armin, Catanese, Maria Teresa, Folgori, Antonella, Colloca, Stefano, Nicosia, Alfredo, and Scarselli, Elisa
- Published
- 2019
- Full Text
- View/download PDF
8. Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer.
- Author
-
D’Alise, Anna Morena, Nocchi, Linda, Garzia, Irene, Seclì, Laura, Infante, Luigia, Troise, Fulvia, Cotugno, Gabriella, Allocca, Simona, Romano, Giuseppina, Lahm, Armin, Leoni, Guido, Sasso, Emanuele, Scarselli, Elisa, and Nicosia, Alfredo
- Subjects
TRANSMISSIBLE tumors ,DNA vaccines ,COMMUNICABLE diseases ,GENETIC vectors ,ADENOVIRUSES - Abstract
Introduction: Virus vectored genetic vaccines (Vvgv) represent a promising approach for eliciting immune protection against infectious diseases and cancer. However, at variance with classical vaccines to date, no adjuvant has been combined with clinically approved genetic vaccines, possibly due to the detrimental effect of the adjuvant-induced innate response on the expression driven by the genetic vaccine vector. We reasoned that a potential novel approach to develop adjuvants for genetic vaccines would be to “synchronize” in time and space the activity of the adjuvant with that of the vaccine. Methods: To this aim, we generated an Adenovirus vector encoding a murine anti-CTLA-4 monoclonal antibody (Ad-9D9) as a genetic adjuvant for Adenovirus based vaccines. Results: The co-delivery of Ad-9D9 with an Adeno-based COVID-19 vaccine encoding the Spike protein resulted in stronger cellular and humoral immune responses. In contrast, only a modest adjuvant effect was achieved when combining the vaccine with the same anti-CTLA-4 in its proteinaceous form. Importantly, the administration of the adjuvant vector at different sites of the vaccine vector abrogates the immunostimulatory effect. We showed that the adjuvant activity of Ad-α-CTLA-4 is independent from the vaccine antigen as it improved the immune response and efficacy of an Adenovirus based polyepitope vaccine encoding tumor neoantigens. Discussion: Our study demonstrated that the combination of Adenovirus Encoded Adjuvant (AdEnA) with an Adeno-encoded antigen vaccine enhances immune responses to viral and tumor antigens, representing a potent approach to develop more effective genetic vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.
- Author
-
D'Alise, Anna Morena and Scarselli, Elisa
- Published
- 2023
- Full Text
- View/download PDF
10. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes
- Author
-
Ugel, Stefano, Scarselli, Elisa, Iezzi, Manuela, Mennuni, Carmela, Pannellini, Tania, Calvaruso, Francesco, Cipriani, Barbara, De Palma, Raffaele, Ricci-Vitiani, Lucia, Peranzoni, Elisa, Musiani, Piero, Zanovello, Paola, and Bronte, Vincenzo
- Published
- 2010
- Full Text
- View/download PDF
11. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection.
- Author
-
D'Alise, Anna Morena, Brasu, Nadia, De Intinis, Carlo, Leoni, Guido, Russo, Valentina, Langone, Francesca, Baev, Denis, Micarelli, Elisa, Petiti, Luca, Picelli, Simone, Fakih, Marwan, Le, Dung T., Overman, Michael J., Shields, Anthony F., Pedersen, Katrina S., Shah, Manish A., Mukherjee, Sarbajit, Faivre, Thea, Delaite, Patricia, and Scarselli, Elisa
- Subjects
T cells ,T cell receptors ,COMBINED vaccines ,IMMUNOLOGIC memory ,CANCER vaccines ,HOMINIDS ,CYTOTOXIC T cells - Abstract
Upon chronic antigen exposure, CD8
+ T cells become exhausted, acquiring a dysfunctional state correlated with the inability to control infection or tumor progression. In contrast, stem-like CD8+ T progenitors maintain the ability to promote and sustain effective immunity. Adenovirus (Ad)–vectored vaccines encoding tumor neoantigens have been shown to eradicate large tumors when combined with anti–programmed cell death protein 1 (αPD-1) in murine models; however, the mechanisms and translational potential have not yet been elucidated. Here, we show that gorilla Ad vaccine targeting tumor neoepitopes enhances responses to αPD-1 therapy by improving immunogenicity and antitumor efficacy. Single-cell RNA sequencing demonstrated that the combination of Ad vaccine and αPD-1 increased the number of murine polyfunctional neoantigen-specific CD8+ T cells over αPD-1 monotherapy, with an accumulation of Tcf1+ stem-like progenitors in draining lymph nodes and effector CD8+ T cells in tumors. Combined T cell receptor (TCR) sequencing analysis highlighted a broader spectrum of neoantigen-specific CD8+ T cells upon vaccination compared to αPD-1 monotherapy. The translational relevance of these data is supported by results obtained in the first 12 patients with metastatic deficient mismatch repair (dMMR) tumors vaccinated with an Ad vaccine encoding shared neoantigens. Expansion and diversification of TCRs were observed in post-treatment biopsies of patients with clinical response, as well as an increase in tumor-infiltrating T cells with an effector memory signature. These findings indicate a promising mechanism to overcome resistance to PD-1 blockade by promoting immunogenicity and broadening the spectrum and magnitude of neoantigen-specific T cells infiltrating tumors. Immunotherapy that is not monkeying around: Adenoviral vaccines encoding for tumor neoantigens have shown promise treating solid tumors when combined with anti–programmed cell death protein 1 (αPD-1) preclinically; however, the mechanism is not well understood. To elucidate this, Chen et al. generated Great Ape adenovirus (GAd) vaccines and treated tumor-bearing mice in combination with αPD-1 to elicit an accumulation of Tcf1+ stem-like CD8+ T cell progenitors, improving immunogenicity and antitumor efficacy. In addition, they performed a first-in-human trial on patients with metastatic mismatch repair–deficient tumors and saw a clinical response, suggesting this as a promising therapy to overcome resistance to αPD-1 treatment. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
12. Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide
- Author
-
Iero, Manuela, Squarcina, Paola, Romero, Pedro, Guillaume, Philippe, Scarselli, Elisa, Cerino, Raffaele, Carrabba, Matteo, Toutirais, Olivier, Parmiani, Giorgio, and Rivoltini, Licia
- Published
- 2007
- Full Text
- View/download PDF
13. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA
- Author
-
Mennuni, Carmela, Calvaruso, Francesco, Facciabene, Andrea, Aurisicchio, Luigi, Storto, Mariangela, Scarselli, Elisa, Ciliberto, Gennaro, and La Monica, Nicola
- Published
- 2005
- Full Text
- View/download PDF
14. Selective deficiency of CD4+/CD45RA+ lymphocytes in patients with ataxia-telangiectasia
- Author
-
Paganelli, Roberto, Scala, Enrico, Scarselli, Elisa, Ortolani, Claudio, Cossarizza, Andrea, Carmini, Daniela, Aiuti, Fernando, and Fiorilli, Massimo
- Published
- 1992
- Full Text
- View/download PDF
15. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries.
- Author
-
Cembrola, Biancamaria, Ruzza, Valentino, Troise, Fulvia, Esposito, Maria Luisa, Sasso, Emanuele, Cafaro, Valeria, Passariello, Margherita, Visconte, Feliciano, Raia, Maddalena, Del Vecchio, Luigi, D'Alise, Anna Morena, Cortese, Riccardo, Scarselli, Elisa, Zambrano, Nicola, De Lorenzo, Claudia, and Nicosia, Alfredo
- Subjects
ANTIGEN analysis ,IMMUNOGLOBULIN analysis ,CELL proliferation ,ANTIGEN-antibody reactions ,FLOW cytometry ,GENE expression ,GENETIC engineering ,IMMUNOGLOBULINS ,LYMPHOCYTES ,MEDICAL protocols ,GENETIC mutation ,YEAST ,SEQUENCE analysis ,IN vitro studies - Abstract
The affinity engineering is a key step to increase the efficacy of therapeutic monoclonal antibodies and yeast surface display is the most widely used and powerful affinity maturation approach, achieving picomolar binding affinities. In this study, we provide an optimization of the yeast surface display methodology, applied to the generation of potentially therapeutic high affinity antibodies targeting the immune checkpoint PD-L1. In this approach, we coupled a 10-cycle error-prone mutagenesis of heavy chain complementarity determining region 3 of an anti‐PD-L1 scFv, previously identified by phage display, with high-throughput sequencing, to generate scFv-yeast libraries with high mutant frequency and diversity. In addition, we set up a novel, faster and effective selection scheme by fluorescence-activated cell sorting, based on a fast drop of the antigen concentration between the first and the last selection cycles, unlike the gradual decrease typical of current selection protocols. In this way we isolated 6 enriched mutated scFv-yeast clones overall, showing an affinity improvement for soluble PD-L1 protein compared to the parental scFv. As a proof of the potency of the novel approach, we confirmed that the antibodies converted from all the mutated scFvs retained the affinity improvement. Remarkably, the best PD-L1 binder among them also bound with a higher affinity to PD-L1 expressed in its native conformation on human-activated lymphocytes, and it was able to stimulate lymphocyte proliferation in vitro more efficiently than its parental antibody. This optimized technology, besides the identification of a new potential checkpoint inhibitor, provides a tool for the quick isolation of high affinity binders. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Longitudinal transcriptomic and genetic landscape of radiotherapy response in canine melanoma.
- Author
-
Giannuzzi, Diana, Marconato, Laura, Elgendy, Ramy, Ferraresso, Serena, Scarselli, Elisa, Fariselli, Piero, Nicosia, Alfredo, Pegolo, Sara, Leoni, Guido, Laganga, Paola, Leone, Vito F., Giantin, Mery, Troise, Fulvia, Dacasto, Mauro, and Aresu, Luca
- Subjects
MELANOMA ,CELL-mediated cytotoxicity ,DIAGNOSIS ,SOMATIC mutation ,RADIOTHERAPY ,RAS oncogenes ,CYCLIN-dependent kinase inhibitor-2A ,DOG diseases ,BRAF genes - Abstract
Canine malignant melanoma (MM) is a highly aggressive tumour with a low survival rate and represents an ideal spontaneous model for the human counterpart. Considerable progress has been recently obtained, but the therapeutic success for canine melanoma is still challenging. Little is known about the mechanisms beyond pathogenesis and melanoma development, and the molecular response to radiotherapy has never been explored before. A faster and deeper understanding of cancer mutational processes and developing mechanisms are now possible through next generation sequencing technologies. In this study, we matched whole exome and transcriptome sequencing in four dogs affected by MM at diagnosis and at disease progression to identify possible genetic mechanisms associated with therapy failure. According to previous studies, a genetic similarity between canine MM and its human counterpart was observed. Several somatic mutations were functionally related to MAPK, PI3K/AKT and p53 signalling pathways, but located in genes other than BRAF, RAS and KIT. At disease progression, several mutations were related to therapy effects. Natural killer cell‐mediated cytotoxicity and several immune‐system‐related pathways resulted activated opening a new scenario on the microenvironment in this tumour. In conclusion, this study suggests a potential role of the immune system associated to radiotherapy in canine melanoma, but a larger sample size associated with functional studies are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
- Author
-
Green, Christopher A., Sande, Charles J., Scarselli, Elisa, Capone, Stefania, Vitelli, Alessandra, Nicosia, Alfredo, Silva-Reyes, Laura, Thompson, Amber J., de Lara, Catherine M., Taylor, Kathryn S., Haworth, Kathryn, Hutchings, Claire L., Cargill, Tamsin, Angus, Brian, Klenerman, Paul, and Pollard, Andrew J.
- Abstract
Objectives: Respiratory syncytial virus (RSV) causes respiratory infection across the world, with infants and the elderly at particular risk of developing severe disease and death. The replication-defective chimpanzee adenovirus (PanAd3-RSV) and modified vaccinia virus Ankara (MVA-RSV) vaccines were shown to be safe and immunogenic in young healthy adults. Here we report an extension to this first-in-man vaccine trial to include healthy older adults aged 60-75 years.Methods: We evaluated the safety and immunogenicity of a single dose of MVA-RSV given by intra-muscular (IM) injection (n = 6), two doses of IM PanAd3-RSV given 4-weeks apart (n = 6), IM PanAd3-RSV prime and IM MVA-RSV boost 8-weeks later (n = 6), intra-nasal (IN) spray of PanAd3-RSV prime and IM MVA-RSV boost 8-weeks later (n = 6), or no vaccine (n = 6). Safety measures included all adverse events within one week of vaccination and blood monitoring. Immunogenicity measures included serum antibody responses (RSV- and PanAd3-neutralising antibody titres measured by plaque-reduction neutralisation and SEAP assays, respectively), peripheral B-cell immune responses (frequencies of F-specific IgG and IgA antibody secreting cells and memory B-cells by ex vivo and cultured dual-colour ELISpot assays respectively), and peripheral RSV-specific T-cell immune responses (frequencies of IFNγ-producing T-cells by ex vivo ELISpot and CD4+/CD8+/Tfh-like cell frequencies by ICS/FACS assay).Results: The vaccines were safe and well tolerated. Compared with each individual baseline immunity the mean fold-changes in serum RSV-neutralising antibody, appearance and magnitude of F-specific IgG and IgA ASCs and expansion of CD4+/CD8+ IFNγ-producing T-cells in peripheral circulation were comparable to the results seen from younger healthy adults who received the same vaccine combination and dose. There were little/no IgA memory B-cell responses in younger and older adults. Expansion of IFNγ-producing T-cells was most marked in older adults following IM prime, with balanced CD4+ and CD8+ T cell responses. The RSV-specific immune responses to vaccination did not appear to be attenuated in the presence of PanAd3 (vector) neutralising antibody.Conclusions: PanAd3-RSV and MVA-RSV was safe and immunogenic in older adults and the parallel induction of RSV-specific humoral and cellular immunity merits further assessment in providing protection from severe disease. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
18. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.
- Author
-
Sasso, Emanuele, D’Avino, Chiara, Passariello, Margherita, D’Alise, Anna Morena, Siciliano, Daniela, Esposito, Maria Luisa, Froechlich, Guendalina, Cortese, Riccardo, Scarselli, Elisa, Zambrano, Nicola, Nicosia, Alfredo, and De Lorenzo, Claudia
- Published
- 2018
- Full Text
- View/download PDF
19. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
- Author
-
Chang, Kyle, Taggart, Melissa W., Reyes-Uribe, Laura, Borras, Ester, Riquelme, Erick, Barnett, Reagan M., Leoni, Guido, San Lucas, F. Anthony, Catanese, Maria T., Mori, Federica, Diodoro, Maria G., You, Y. Nancy, Hawk, Ernest T., Roszik, Jason, Scheet, Paul, Kopetz, Scott, Nicosia, Alfredo, Scarselli, Elisa, Lynch, Patrick M., and McAllister, Florencia
- Published
- 2018
- Full Text
- View/download PDF
20. Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane.
- Author
-
Vitelli, Alessandra, Folgori, Antonella, Scarselli, Elisa, Colloca, Stefano, Capone, Stefania, and Nicosia, Alfredo
- Abstract
Introduction: In recent years, replication-defective chimpanzee-derived adenoviruses have been extensively evaluated as genetic vaccines. These vectors share desirable properties with human adenoviruses like the broad tissue tropism and the ease of large-scale manufacturing. Additionally, chimpanzee adenoviruses have the advantage to overcome the negative impact of pre-existing anti-human adenovirus immunity. Areas covered: Here the authors review current pre-clinical research and clinical trials that utilize chimpanzee-derived adenoviral vectors as vaccines. A wealth of studies are ongoing to evaluate different vector backbones and administration routes with the aim of improving immune responses. The challenges associated with the identification of an optimal chimpanzee vector and immunization strategies for different immunological outcomes will be discussed. Expert commentary: The demonstration that chimpanzee adenoviruses can be safely used in humans has paved the way to the use of a whole new array of vectors of different serotypes. However, so far no predictive signature of vector immunity in humans has been identified. The high magnitude of T cell responses elicited by chimpanzee adenoviruses has allowed dissecting the qualitative aspects that may be important for protective immunity. Ultimately, only the results from the most clinically advanced products will help establish the efficacy of the vaccine vector platform in the field of disease prevention. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
21. Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.
- Author
-
Overman, Michael J., Maurel, Joan, Oberstein, Paul Eliezer, Roselló-Keränen, Susana, Le, Dung T., Pedersen, Katrina Sophia, Mukherjee, Sarbajit, D'Alise, Anna Morena, Leoni, Guido, Siani, Loredana, Scarselli, Elisa, Faivre, Théa, Delaite, Patricia, Gogov, Sven, and Fakih, Marwan
- Published
- 2023
- Full Text
- View/download PDF
22. Antibody response to respiratory syncytial virus infection in children <18 months old.
- Author
-
Esposito, Susanna, Scarselli, Elisa, Lelii, Mara, Scala, Alessia, Vitelli, Alessandra, Capone, Stefania, Fornili, Marco, Biganzoli, Elia, Orenti, Annalisa, Nicosia, Alfredo, Cortese, Riccardo, and Principi, Nicola
- Published
- 2016
- Full Text
- View/download PDF
23. Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
- Author
-
Green, Christopher A., Scarselli, Elisa, Sande, Charles J., Thompson, Amber J., de Lara, Catherine M., Taylor, Kathryn S., Haworth, Kathryn, Sorbo, Mariarosaria Del, Angus, Brian, Siani, Loredana, Di Marco, Stefania, Traboni, Cinzia, Folgori, Antonella, Colloca, Stefano, Capone, Stefania, Vitelli, Alessandra, Cortese, Riccardo, Klenerman, Paul, Nicosia, Alfredo, and Pollard, Andrew J.
- Subjects
RESPIRATORY syncytial virus infection vaccines ,PALIVIZUMAB ,MONOCLONAL antibodies ,PREVENTIVE medicine ,IMMUNOPATHOLOGY ,RESPIRATORY diseases ,THERAPEUTICS - Abstract
The article offers information on the efficacy of chimpanzee adenovirus, PanAd3-RSV, and modified vaccinia virus Ankara, MVA-RSV in the vaccination of respiratory syncytial virus (RSV) infection. It mentions the limitation of palivizumab monoclonal antibody prophylaxis; talks about the absence of immunopathology associated with enhanced respiratory disease (ERD) after vaccination; and investigated the cellular immunogenicity of the vaccines.
- Published
- 2015
- Full Text
- View/download PDF
24. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.
- Author
-
Taylor, Geraldine, Thom, Michelle, Capone, Stefania, Pierantoni, Angiolo, Guzman, Efrain, Herbert, Rebecca, Scarselli, Elisa, Napolitano, Federico, Giuliani, Alessandro, Folgori, Antonella, Colloca, Stefano, Cortese, Riccardo, Nicosia, Alfredo, and Vitelli, Alessandra
- Subjects
RESPIRATORY syncytial virus infection vaccines ,RESPIRATORY syncytial virus infections ,DRUG efficacy ,INFANT diseases ,BOVINE respiratory syncytial virus diseases - Abstract
The article offers information on a study concerning the efficacy of virus-vectored vaccine against human respiratory syncytial virus (HRSV) infections. Topics discussed include major barriers to vaccine development associated with the young age of the main target population and the history of vaccine-exacerbated disease in infants; similarities between HRSV and bovine respiratory syncytial virus (BRSV) infections; and limitations of the study.
- Published
- 2015
- Full Text
- View/download PDF
25. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
- Author
-
Diaz-Montero, Claudia Marcela, Chiappori, Alberto, Aurisicchio, Luigi, Bagchi, Ansuman, Clark, Jason, Dubey, Sheri, Fridman, Arthur, Fabregas, Jesus C., Marshall, John, Scarselli, Elisa, La Monica, Nicola, Ciliberto, Gennaro, and Montero, Alberto J.
- Subjects
ELECTROPORATION therapy ,DNA vaccines ,ADENOVIRUSES ,IMMUNIZATION ,CELLULAR immunity ,IMMUNE response ,ESCHERICHIA coli - Abstract
Background: DNA electroporation has been demonstrated in preclinical models to be a promising strategy to improve cancer immunity, especially when combined with other genetic vaccines in heterologous prime-boost protocols. We report the results of 2 multicenter phase 1 trials involving adult cancer patients (n=33) with stage II-IV disease. Methods: Patients were vaccinated with V930 alone, a DNA vaccine containing equal amounts of plasmids expressing the extracellular and trans-membrane domains of human HER2, and a plasmid expressing CEA fused to the B subunit of Escherichia coli heat labile toxin (Study 1), or a heterologous prime-boost vaccination approach with V930 followed by V932, a dicistronic adenovirus subtype-6 viral vector vaccine coding for the same antigens (Study 2). Results: The use of the V930 vaccination with electroporation alone or in combination with V932 was welltolerated without any serious adverse events. In both studies, the most common vaccine-related side effects were injection site reactions and arthralgias. No measurable cell-mediated immune response (CMI) to CEA or HER2 was detected in patients by ELISPOT; however, a significant increase of both cell-mediated immunity and antibody titer against the bacterial heat labile toxin were observed upon vaccination. Conclusion: V930 vaccination alone or in combination with V932 was well tolerated without any vaccine-related serious adverse effects, and was able to induce measurable immune responses against bacterial antigen. However, the prime-boost strategy did not appear to augment any detectable CMI responses against either CEA or HER2. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
26. Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance.
- Author
-
Gentile, Chiara, Finizio, Arianna, Froechlich, Guendalina, D'Alise, Anna Morena, Cotugno, Gabriella, Amiranda, Sara, Nicosia, Alfredo, Scarselli, Elisa, Zambrano, Nicola, and Sasso, Emanuele
- Subjects
ADENOSINE deaminase ,ADENOSINES ,EXTRACELLULAR enzymes ,PEPTIDES ,PURINERGIC receptors ,CANCER cells - Abstract
Background: Oncolytic viruses are immunotherapeutic agents that can be engineered to encode payloads of interest within the tumor microenvironment to enhance therapeutic efficacy. Their therapeutic potential could be limited by many avenues for immune evasion exerted by the tumor. One such is mediated by adenosine, which induces pleiotropic immunosuppression by inhibiting antitumor immune populations as well as activating tolerogenic stimuli. Adenosine is produced starting from the highly immunostimulatory ATP, which is progressively hydrolyzed to ADP and adenosine by CD39 and CD73. Cancer cells express high levels of CD39 and CD73 ectoenzymes, thus converting immunostimulatory purinergic signal of ATP into an immunosuppressive signal. For this reason, CD39, CD73 and adenosine receptors are currently investigated in clinical trials as targets for metabolic cancer immunotherapy. This is of particular relevance in the context of oncovirotherapy, as immunogenic cell death induced by oncolytic viruses causes the secretion of a high amount of ATP which is available to be quickly converted into adenosine. Methods: Here, we took advantage of adenosine deaminase enzyme that naturally converts adenosine into the corresponding inosine derivative, devoid of immunoregulatory function. We encoded ADA into an oncolytic targeted herpes virus redirected to human HER2. An engineered ADA with an ectopic signal peptide was also generated to improve enzyme secretion (ADA-SP). Results: Insertion of the expression cassette was not detrimental for viral yield and cancer cell cytotoxicity. The THV_ADA and THV_ADA-SP successfully mediated the secretion of functional ADA enzyme. In in vitro model of human monocytes THP1, this ability of THV_ADA and THV_ADA-SP resulted in the retrieval of eADO-exposed monocytes replication rate, suggesting the proficiency of the viruses in rescuing the immune function. Conclusions: Encoding ADA into oncolytic viruses revealed promising properties for preclinical exploitation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide.
- Author
-
Iero, Manuela, Squarcina, Paola, Romero, Pedro, Guillaume, Philippe, Scarselli, Elisa, Cerino, Raffaele, Carrabba, Matteo, Toutirais, Olivier, Parmiani, Giorgio, and Rivoltini, Licia
- Subjects
T-cell receptor genes ,CELLULAR recognition ,PEPTIDES ,EPITOPES ,IMMUNOGENETICS - Abstract
The use of “altered peptide ligands” (APL), epitopes designed for exerting increased immunogenicity as compared with native determinants, represents nowadays one of the most utilized strategies for overcoming immune tolerance to self-antigens and boosting anti-tumor T cell-mediated immune responses. However, the actual ability of APL-primed T cells to cross-recognize natural epitopes expressed by tumor cells remains a crucial concern. In the present study, we show that CAP1-6D, a superagonist analogue of a carcinoembriyonic antigen (CEA)-derived HLA-A*0201-restricted epitope widely used in clinical setting, reproducibly promotes the generation of low-affinity CD8
+ T cells lacking the ability to recognized CEA-expressing colorectal carcinoma (CRC) cells. Short-term T cell cultures, obtained by priming peripheral blood mononuclear cells from HLA-A*0201+ healthy donors or CRC patients with CAP1-6D, were indeed found to heterogeneously cross-react with saturating concentrations of the native peptide CAP1, but to fail constantly lysing or recognizing through IFN- γ release CEA+ CRC cells. Characterization of anti-CAP1-6D T cell avidity, gained through peptide titration, CD8-dependency assay, and staining with mutated tetramers (D227K/T228A), revealed that anti-CAP1-6D T cells exerted a differential interaction with the two CEA epitopes, i.e., displaying high affinity/CD8-independency toward the APL and low affinity/CD8-dependency toward the native CAP1 peptide. Our data demonstrate that the efficient detection of self-antigen expressed by tumors could be a feature of high avidity CD8-independent T cells, and underline the need for extensive analysis of tumor cross-recognition prior to any clinical usage of APL as anti-cancer vaccines. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
28. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.
- Author
-
Scarselli, Elisa, Ansuini, Helenia, Cerino, Raffaele, Roccasecca, Rosa Maria, Acali, Stefano, Filocamo, Gessica, Traboni, Cinzia, Nicosia, Alfredo, Cortese, Riccardo, and Vitelli, Alessandra
- Subjects
- *
HEPATITIS C virus , *HEPATOCELLULAR carcinoma , *LIVER cells , *CELL lines , *LIVER diseases , *CELL culture - Abstract
We discovered that the hepatitis C virus (HCV) envelope glycoprotein E2 binds to human hepatoma cell lines independently of the previously proposed HCV receptor CD81. Comparative binding studies using recombinant E2 from the most prevalent la and lb genotypes revealed that E2 recognition by hepatoma cells is independent from the viral isolate, while E2-CD81 interaction is isolate specific. Binding of soluble E2 to human hepatoma cells was impaired by deletion of the hypervariable region 1 (HYR1), but the wild-type phenotype was recovered by introducing a compensatory mutation reported previously to rescue infectivity of an HYR1-deleted HCV infectious clone. We have identified the receptor responsible for E2 binding to human hepatic cells as the human scavenger receptor class B type I (SR-BI). E2-SR-BI interaction is very selective since neither mouse SR-BI nor the closely related human scavenger receptor CD36, were able to bind E2. Finally, E2 recognition by SR-BI was competed out in an isolate-specific manner both on the hepatoma cell line and on the human SR-BI-transfected cell line by an anti-HYR1 monoclonal antibody. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
29. VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens' Prediction.
- Author
-
Leoni, Guido, D'Alise, Anna Morena, Tucci, Fabio Giovanni, Micarelli, Elisa, Garzia, Irene, De Lucia, Maria, Langone, Francesca, Nocchi, Linda, Cotugno, Gabriella, Bartolomeo, Rosa, Romano, Giuseppina, Allocca, Simona, Troise, Fulvia, Nicosia, Alfredo, Lahm, Armin, and Scarselli, Elisa
- Subjects
VENUS (Planet) ,MAJOR histocompatibility complex ,T cells - Abstract
Neoantigens are tumor-specific antigens able to induce T-cell responses, generated by mutations in protein-coding regions of expressed genes. Previous studies demonstrated that only a limited subset of mutations generates neoantigens in microsatellite stable tumors. We developed a method, called VENUS (Vaccine-Encoded Neoantigens Unrestricted Selection), to prioritize mutated peptides with high potential to be neoantigens. Our method assigns to each mutation a weighted score that combines the mutation allelic frequency, the abundance of the transcript coding for the mutation, and the likelihood to bind the patient's class-I major histocompatibility complex alleles. By ranking mutated peptides encoded by mutations detected in nine cancer patients, VENUS was able to select in the top 60 ranked peptides, the 95% of neoantigens experimentally validated including both CD8 and CD4 T cell specificities. VENUS was evaluated in a murine model in the context of vaccination with an adeno vector encoding the top ranked mutations prioritized in the MC38 cell line. Efficacy studies demonstrated anti tumoral activity of the vaccine when used in combination with checkpoint inhibitors. The results obtained highlight the importance of a combined scoring system taking into account multiple features of each tumor mutation to improve the accuracy of neoantigen prediction. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes.
- Author
-
Zambello, Renato, Pizzolo, Giovanni, Trentin, Livio, Agostini, Carlo, Chisesi, Teodoro, Vinante, Fabrizio, Scarselli, Elisa, Zanotti, Roberta, Vespignani, Michele, De Rossi, Giulio, Pandolfi, Franco, Semenzato, Gianpietro, Zambello, R, Pizzolo, G, Trentin, L, Agostini, C, Chisesi, T, Vinante, F, Scarselli, E, and Zanotti, R
- Published
- 1989
- Full Text
- View/download PDF
31. Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing.
- Author
-
Froechlich, Guendalina, Gentile, Chiara, Infante, Luigia, Caiazza, Carmen, Pagano, Pasqualina, Scatigna, Sarah, Cotugno, Gabriella, D'Alise, Anna Morena, Lahm, Armin, Scarselli, Elisa, Nicosia, Alfredo, Mallardo, Massimo, Sasso, Emanuele, and Zambrano, Nicola
- Subjects
HERPESVIRUS diseases ,GERM cells ,TUMOR antigens ,VIRUS diseases ,HERPES simplex ,CD19 antigen - Abstract
Background: HER2-based retargeted viruses are in advanced phases of preclinical development of breast cancer models. Mesothelin (MSLN) is a cell-surface tumor antigen expressed in different subtypes of breast and non-breast cancer. Its recent identification as a marker of some triple-negative breast tumors renders it an attractive target, presently investigated in clinical trials employing antibody drug conjugates and CAR-T cells. The availability of MSLN-retargeted oncolytic viruses may complement the current immunotherapeutic panel of biological drugs against HER2-negative breast and non-breast tumors. Methods: A fully virulent, tumor-targeted oncolytic Herpes simplex virus-1 (MSLN-THV) with a selectivity for mesothelin-expressing cancer cells was generated. Recombineering technology was used to replace an essential moiety of the viral glycoprotein D with antibody fragments derived from clinically validated MSLN monoclonal antibodies, and to allow IL12 cargo expression in infected cells. Panels of breast and female reproductive system cell lines were used to verify the oncolytic potential of the viral constructs. A platform for production of the retargeted viruses was developed in HEK 293 cells, providing stable expression of a suitable chimeric receptor. Results: We demonstrated the selectivity of viral infection and cytotoxicity by MSLN-retargeted viruses in a panel of mesothelin-positive cancer cells, originating from breast and female reproductive system tumors. We also developed a second-generation oncolytic MSLN-THV, encoding IL12, to enhance the immunotherapeutic potential of the viral backbone. A non-tumor cell line expressing a chimeric MSLN/Nectin-1 receptor, de-sensitized from antiviral responses by genetic inactivation of the Stimulator of Interferon Genes (STING)-dependent pathway was engineered, to optimize viral yields. Conclusions: Our proof-of-concept study proposes MSLN-retargeted herpesviruses as potential cancer immunotherapeutics for assessments in preclinical models of MSLN-positive tumors, complementing the available panel of oncolytic viruses to HER2-negative breast tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus.
- Author
-
Froechlich, Guendalina, Caiazza, Carmen, Gentile, Chiara, D'Alise, Anna Morena, De Lucia, Maria, Langone, Francesca, Leoni, Guido, Cotugno, Gabriella, Scisciola, Vittorio, Nicosia, Alfredo, Scarselli, Elisa, Mallardo, Massimo, Sasso, Emanuele, and Zambrano, Nicola
- Subjects
ANIMAL experimentation ,ANTINEOPLASTIC agents ,BIOLOGICAL models ,BIOTHERAPY ,CELL death ,CELL physiology ,DNA ,HERPES simplex ,HERPESVIRUSES ,IMMUNE response ,IMMUNITY ,IMMUNOCOMPETENT cells ,IMMUNOTHERAPY ,MICE ,RNA ,TUMORS ,GENE expression profiling ,IN vitro studies ,IN vivo studies ,IMMUNE checkpoint inhibitors - Abstract
Simple Summary: Oncolytic viruses are emerging immunotherapeutics in cancer treatments. The conflicting role of innate immunity in the antitumor activity of oncolytic viruses is still a matter of debate. The STING-dependent DNA sensing axis is considered detrimental for viral replication and cancer cell clearance. Accordingly, we observed that STING loss in tumor cells was associated with improved lytic potential by a herpes-based oncolytic virus. However, STING-knockout cancer cells infected with the oncolytic virus showed impaired immunogenicity, as immunogenic cell death was improperly triggered. In agreement with these observations, STING-knockout tumors raised in a murine syngeneic model were more resistant to a combined treatment of the oncolytic virus with PD-1 blockade. The present study demonstrates the antitumor benefit of antiviral immunity and sheds lights on the mechanisms of immune resistance to oncovirotherapy exerted by STING-loss in tumor cells. The dichotomic contribution of cancer cell lysis and tumor immunogenicity is considered essential for effective oncovirotherapy, suggesting that the innate antiviral immune response is a hurdle for efficacy of oncolytic viruses. However, emerging evidence is resizing this view. By sensing cytosolic DNA, the cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) axis can both counteract viral spread and contribute to the elicitation of adaptive immunity via type I interferon responses. In this paper, we analyzed the tumor-resident function of Sting-mediated DNA sensing in a combined approach of oncovirotherapy and PD-1 immune checkpoint blockade, in an immunocompetent murine model. While supporting increased lytic potential by oncolytic HER2-retargeted HSV-1 in vitro and in vivo, Sting-knockout tumors showed molecular signatures of an immunosuppressive tumor microenvironment. These signatures were correspondingly associated with ineffectiveness of the combination therapy in a model of established tumors. Results suggest that the impairment in antiviral response of Sting-knockout tumors, while favoring viral replication, is not able to elicit an adequate immunotherapeutic effect, due to lack of immunogenic cell death and the inability of Sting-knockout cancer cells to promote anti-tumor adaptive immune responses. Accordingly, we propose that antiviral, tumor-resident Sting provides fundamental contributions to immunotherapeutic efficacy of oncolytic viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells.
- Author
-
Passariello, Margherita, Vetrei, Cinzia, Sasso, Emanuele, Froechlich, Guendalina, Gentile, Chiara, D'Alise, Anna Morena, Zambrano, Nicola, Scarselli, Elisa, Nicosia, Alfredo, and De Lorenzo, Claudia
- Subjects
ANTIGEN analysis ,ANIMAL experimentation ,ANTINEOPLASTIC agents ,CELL lines ,IMMUNOTHERAPY ,KILLER cells ,LIGANDS (Biochemistry) ,MICE ,TUMORS ,IPILIMUMAB ,PHARMACODYNAMICS - Abstract
The cytotoxic T lymphocyte-antigen 4 (CTLA-4) has been considered an IC exclusively expressed on T cells, where it counteracts the co-stimulatory CD28 receptor, by competing for its binding to CD-80 and CD-86. We recently found that it is expressed also on tumor and NK cells, suggesting other possible unknown roles of CTLA-4. To shed light on these novel aspects of CTLA-4, we used Ipilimumab, the first FDA approved human antibody targeting CTLA-4, in parallel studies with two novel human mAbs we isolated by using an efficient phage display selection strategy on live activated lymphocytes and purified mouse and human CTLA-4. The selection for cross-reactive mAbs was guaranteed by a high throughput sequencing to identify the sequences commonly enriched by two parallel pannings on human and mouse CTLA-4. Two isolated antibodies were found to bind with high affinity to both human and mouse CTLA-4 and lymphocytes, showing nanomolar or sub-nanomolar Kd values. They were able to kill Treg cells by ADCC, and to activate both human and mouse PBMCs, by strongly increasing cytokines secretion. Interestingly, they activated NK cells, exhibited cytotoxicity against cancer cells by inducing ADCC and inhibited tumor cell growth by affecting CTLA-4 downstream pathways in a similar fashion to CD-80 and CD-86 ligands and differently from Ipilimumab. Moreover, the novel mAbs showed a reduced ability to interfere in the binding of CD-80 ligands to CTLA-4 on T cells with respect to Ipilimumab, suggesting that they could allow for anti-tumor effects without the irAEs associated with the potent antagonistic activity of Ipilimumab. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
34. LB10. A Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Vaccine to Prevent Chronic Hepatitis C Virus Infection in an at-Risk Population.
- Author
-
Cox, Andrea L, Page, Kimberly, Melia, Michael, Veenhuis, Rebecca, Massaccesi, Guido, Osburn, William, Wagner, Katherine, Giudice, Linda, Stein, Ellen, Asher, Alice K, Vassilev, Ventzislav, Lin, Lan, Nicosia, Alfredo, Capone, Stefania, Scarselli, Elisa, Folgori, Antonella, Gorman, Richard, Chang, Soju, Wolff, Peter, and Liang, T Jake
- Subjects
CHRONIC hepatitis C ,HEPATITIS C virus ,VIRUS diseases ,VACCINE effectiveness ,IMMUNIZATION of children ,NEUTRALIZATION tests ,LOCAL area networks - Abstract
Background The development of a safe and effective vaccine to prevent chronic hepatitis C virus (HCV) infection is a critical component of elimination efforts, providing the rationale for the first HCV vaccine efficacy trial. Methods In a randomized, multicenter, double-blind, placebo-controlled efficacy trial (NCT01436357), we evaluated a recombinant chimpanzee adenovirus 3 vector vaccine prime followed by a recombinant modified vaccinia Ankara boost, both encoding nonstructural proteins of HCV. HCV-uninfected adults 18–45 years old at-risk for HCV infection due to injection drug use were randomized to receive the prime-boost regimen or placebo at Days 0 and 56. Trial participants were monitored for vaccine reactogenicity, adverse events, and HCV viremia. Vaccine safety, immunogenicity, and efficacy against progression to chronic HCV infection were assessed. Results A total of 455 subjects received the prime-boost regimen or two doses of placebo, with 202 and 199 in the respective groups included in the according-to-protocol efficacy cohort. Overall incidence of infection was 14.1 infections per 100 person-years. There were no differences in development of chronic infection between vaccine and placebo arms, with 14 chronically infected subjects in each group. Specifically, the vaccine efficacy in preventing chronic infection was −0.53 (95% confidence interval [CI], −2.5 to 0.34). Of vaccinated subjects, 78% generated T-cell responses to ≥1 vaccine-encoded HCV antigens. The vaccine was generally safe and well tolerated with no serious vaccine-related adverse events. There were more solicited reports of adverse events after either injection in the vaccine group (81%) than in the placebo group (59%), with the difference mainly due to injection-site reactions. Serious adverse events and deaths occurred with similar frequencies in the two groups. Conclusion A randomized, placebo controlled, Phase I/II trial of a prime-boost vaccine to prevent chronic HCV infection was completed in an at-risk population, demonstrating the feasibility of conducting rigorous vaccine research in people who inject drugs. The regimen elicited robust immune responses without evident safety concerns, but did not provide protection against chronic HCV infection. Disclosures Ventzislav Vassilev, PhD, GlaxoSmithKlein Vaccines (Employee), Lan Lin, MD, GlaxoSmithKlein Vaccines (Employee), Alfredo Nicosia, PhD, ReiThera (Employee, Shareholder), Antonella Folgori, PhD, ReiThera (Employee), ReiThera (Employee, Shareholder. Other Authors: No reported disclosures. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.
- Author
-
D'Alise, Anna Morena, Leoni, Guido, Cotugno, Gabriella, Troise, Fulvia, Langone, Francesca, Fichera, Imma, De Lucia, Maria, Avalle, Lidia, Vitale, Rosa, Leuzzi, Adriano, Bignone, Veronica, Di Matteo, Elena, Tucci, Fabio Giovanni, Poli, Valeria, Lahm, Armin, Catanese, Maria Teresa, Folgori, Antonella, Colloca, Stefano, Nicosia, Alfredo, and Scarselli, Elisa
- Abstract
Neoantigens (nAgs) are promising tumor antigens for cancer vaccination with the potential of inducing robust and selective T cell responses. Genetic vaccines based on Adenoviruses derived from non-human Great Apes (GAd) elicit strong and effective T cell-mediated immunity in humans. Here, we investigate for the first time the potency and efficacy of a novel GAd encoding multiple neoantigens. Prophylactic or early therapeutic vaccination with GAd efficiently control tumor growth in mice. In contrast, combination of the vaccine with checkpoint inhibitors is required to eradicate large tumors. Gene expression profile of tumors in regression shows abundance of activated tumor infiltrating T cells with a more diversified TCR repertoire in animals treated with GAd and anti-PD1 compared to anti-PD1. Data suggest that effectiveness of vaccination in the presence of high tumor burden correlates with the breadth of nAgs-specific T cells and requires concomitant reversal of tumor suppression by checkpoint blockade. Vaccination against neo-antigens has resulted in an effective antitumor response in several models. Here, the authors show that delivery of larger sets of neo-antigens using an adenovirus-based vaccination platform, results in much better tumor protection when combined with checkpoint blockade in a mouse model of advanced disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. A novel minigene scaffold for therapeutic cancer vaccines.
- Author
-
Aurisicchio, Luigi, Fridman, Arthur, Bagchi, Ansuman, Scarselli, Elisa, La Monica, Nicola, and Ciliberto, Gennaro
- Subjects
TISSUE scaffolds ,CANCER vaccines ,T cells ,CANCER immunotherapy ,CARCINOEMBRYONIC antigen ,GENETIC transformation ,CANCER cells ,EPITOPES - Abstract
Genetic vaccines are emerging as a powerful modality to induce T-cell responses to target tumor associated antigens (TAA). Viral or plasmid DNA or RNA vectors harbor an expression cassette encoding the antigen of choice delivered in vivo by vaccination. In this context, immunizations with minigenes containing selected, highly antigenic, T-cell epitopes of TAAs may have several advantages relative to full-length proteins. The objective of this study was to identify an optimal scaffold for minigene construction. We generated a number of minigenes containing epitopes from the carcinoembryonic antigen (CEA) model TAA and utilized muscle DNA electro-gene-transfer (DNA-EGT) to vaccinate HLA-A*0201 (HHD) and CEA/HHD double transgenic mice. The components utilized to construct the minigenes included CD8+T cell epitopes and (or) anchor modified analogs that were selected on the basis of their predicted binding to HLA-*A0201, their uniqueness in the human proteome, and the likelihood of cancer cell natural processing and presentation via MHC-I. Other candidate components comparatively tested included: helper CD4+T-cell epitopes, flanking regions for optimal epitope processing (including both proteasome-dependent and furin-dependent polypeptide processing mechanisms), and immunoenhancing moieties. Through a series of comparative studies and iterations we have identified an optimal minigene scaffold comprising the following elements: human tissue plasminogen activator (TPA) signal peptide, T-cell epitopes connected by furin sensitive linkers, and theE. Colienterotoxin B subunit. The selected epitope modified minigenes (EMM) delivered by DNA-EGT were able to break immune tolerance in CEA/HHD mice and induce a strong immune response against all epitopes tested, independently of their relative positions within the scaffold. Furthermore, the optimized EMMs delivered via DNA-EGT were more immunogenic and exerted more powerful antitumor effects in a B16-CEA/HHD metastatic melanoma model than a DNA vector encoding the full-length protein or a mixture of the same peptides injected subcutaneously. Our data may shed light on the optimal design of a universal vehicle for epitope-targeted, genetic cancer vaccines. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
37. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
- Author
-
Diaz-Montero, Claudia Marcela, Chiappori, Alberto, Aurisicchio, Luigi, Bagchi, Ansuman, Clark, Jason, Dubey, Sheri, Fridman, Arthur, Fabregas, Jesus C, Marshall, John, Scarselli, Elisa, La Monica, Nicola, Ciliberto, Gennaro, Montero, Alberto J, and Diaz, Claudia Marcela
- Abstract
Background: DNA electroporation has been demonstrated in preclinical models to be a promising strategy to improve cancer immunity, especially when combined with other genetic vaccines in heterologous prime-boost protocols. We report the results of 2 multicenter phase 1 trials involving adult cancer patients (n=33) with stage II-IV disease.Methods: Patients were vaccinated with V930 alone, a DNA vaccine containing equal amounts of plasmids expressing the extracellular and trans-membrane domains of human HER2, and a plasmid expressing CEA fused to the B subunit of Escherichia coli heat labile toxin (Study 1), or a heterologous prime-boost vaccination approach with V930 followed by V932, a dicistronic adenovirus subtype-6 viral vector vaccine coding for the same antigens (Study 2).Results: The use of the V930 vaccination with electroporation alone or in combination with V932 was well-tolerated without any serious adverse events. In both studies, the most common vaccine-related side effects were injection site reactions and arthralgias. No measurable cell-mediated immune response (CMI) to CEA or HER2 was detected in patients by ELISPOT; however, a significant increase of both cell-mediated immunity and antibody titer against the bacterial heat labile toxin were observed upon vaccination.Conclusion: V930 vaccination alone or in combination with V932 was well tolerated without any vaccine-related serious adverse effects, and was able to induce measurable immune responses against bacterial antigen. However, the prime-boost strategy did not appear to augment any detectable CMI responses against either CEA or HER2.Trial Registration: Study 1 - ClinicalTrials.gov, NCT00250419; Study 2 - ClinicalTrials.gov, NCT00647114. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
38. Receptor phage: Display of functional domains of the human high affinity IgE receptor on the M13 phage surface
- Author
-
Scarselli, Elisa, Esposito, Gloria, and Traboni, Cinzia
- Published
- 1993
- Full Text
- View/download PDF
39. A Vaccine Targeting Telomerase Enhances Survival of Dogs Affected by B-cell Lymphoma.
- Author
-
Peruzzi, Daniela, Gavazza, Alessandra, Mesiti, Giuseppe, Lubas, George, Scarselli, Elisa, Conforti, Antonella, Bendtsen, Claus, Ciliberto, Gennaro, La Monica, Nicola, and Aurisicchio, Luigi
- Subjects
- *
DOG vaccination , *CANCER in animals , *TELOMERASE , *B cells , *LYMPHOMAS , *DRUG therapy , *IMMUNE response - Abstract
Canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histological appearance, tumor genetics, biological behavior, and response to conventional therapies. As observed in humans, the telomerase reverse transcriptase (TERT) activity is largely confined to tumor tissues and absent in the majority of normal dog tissues. Therefore, dog TERT (dTERT) can constitute a valid target for translational cancer immunotherapy. We have evaluated the ability of adenovirus serotype 6 (Ad6) and DNA electroporation (DNA-EP) to induce immune responses against dTERT in dogs affected by malignant lymphoma (ML). The vaccine was combined with standard chemotherapy regimen [cyclophosphamide, vincristine, prednisone (COP)]. dTERT-specific immune response was induced in 13 out of 14 treated animals (93%) and remained detectable and long-lasting with the absence of autoimmunity or other side effects. Most interestingly, the survival time of vaccine/Chemo-treated dogs was significantly increased over historic controls of Chemo-treated animals (>97.8 versus 37 weeks, respectively, P = 0.001). Our results show that Ad6/DNA-EP-based cancer vaccine against dTERT overcomes host immune tolerance, should be combined with chemotherapy, induces long-lasting immune responses, and significantly prolongs the survival of ML canine patients. These data support further evaluation of this approach in human clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
40. Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman Primates.
- Author
-
Dharmapuri, Sridhar, Peruzzi, Daniela, Mennuni, Carmela, Calvaruso, Francesco, Giampaoli, Saverio, Barbato, Gaetano, Kandimalla, Ekambar R, Agrawal, Sudhir, Scarselli, Elisa, Mesiti, Giuseppe, Ciliberto, Gennaro, La Monica, Nicola, and Aurisicchio, Luigi
- Subjects
- *
TELOMERASE , *DNA polymerases , *DNA vaccines , *CANCER treatment , *CYTOKINES , *CELLULAR immunity - Abstract
The human telomerase reverse transcriptase (hTERT) is an attractive target for human cancer vaccination because its expression is reactivated in most human tumors. We have evaluated the ability of DNA electroporation (DNA-EP) and adenovirus serotype 6 (Ad6) to induce immune responses against hTERT in nonhuman primates (NHPs) (Macaca mulatta). Vaccination was effective in all treated animals, and the adaptive immune response remained detectable and long lasting without side effects. To further enhance the efficacy of the hTERT vaccine, we evaluated the combination of hTERT vaccine and a novel TLR9 agonist, referred to as immunomodulatory oligonucleotide (IMO). Monkeys were dosed weekly with IMO concurrently with the vaccine regimen and showed increases in cytokine secretion and activation of natural killer (NK) cells compared with the group that received vaccine alone. Using a peptide array, a specific profile of B-cell reactive epitopes was identified when hTERT vaccine was combined with IMO. The combination of IMO with hTERT genetic vaccine did not impact vaccine-induced TERT-specific cell-mediated immunity. Our results show that appropriate combination of a DNA-EP/Ad6-based cancer vaccine against hTERT with IMO induces multiple effects on innate and adaptive immune responses in NHPs. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
41. Scavenger Receptor Class B Type I and Hepatitis C Virus Infection of Primary Tupaia Hepatocytes.
- Author
-
Barth, Heidi, Cerino, Raffaele, Arcuri, Mirko, Hoffmann, Marco, Schurmann, Peter, Adah, Mohammed I., Gissler, Bettina, Xiping Zhao, Ghisetti, Valeria, Lavezzo, Bruna, Blum, Hubert E., Von Weizsäcker, Fritz, Vitelli, Alessandra, Scarselli, Elisa, and Baumert, Thomas F.
- Subjects
- *
HEPATITIS C , *HEPATITIS C virus , *LIVER cells , *CELL receptors , *TUPAIA , *GLYCOPROTEINS - Abstract
Hepatitis C virus (HCV) is a major cause of chronic hepatitis worldwide. The study of early steps during HCV infection has been hampered by the lack of suitable in vitro or in vivo models. Primary Tupaia hepatocytes (PTH) have been shown to be susceptible to HCV infection in vitro and in vivo. Human scavenger receptor class B type I (SR-BI) represents an HCV receptor candidate mediating the cellular binding of E2 glycoprotein to HepG2 hepatoma cells. However, the function of SR-BI for viral infection of hepatocytes is unknown. In this study, we used PTH to assess the functional role of SR-BI as a putative HCV receptor. Sequence analysis of cloned tupaia SR-BI revealed a high homology between tupaia and human SR-BI. Transfection of CHO cells with human or tupaia SR-BI but not mouse SR-BI cDNA resulted in cellular E2 binding, suggesting that E2-binding domains between human and tupaia SR-BI are highly conserved. Preincubation of PTH with anti-SR-BI antibodies resulted in marked inhibition of E2 or HCV-like particle binding. However, anti-SR-BI antibodies were not able to block HCV infection of PTH. In conclusion, our results demonstrate that SR-BI represents an important cell surface molecule for the binding of the HCV envelope to hepatocytes and suggest that other or additional cell surface molecules are required for the initiation of HCV infection. Furthermore, the structural and functional similarities between human and tupaia SR-BI indicate that PTH represent a useful model system to characterize the molecular interaction of the HCV envelope and SR-BI on primary hepatocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
42. Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor.
- Author
-
Bartosch, Birke, Vitelli, Alessandra, Granier, Christelle, Goujon, Caroline, Dubuisson, Jean, Pascale, Simona, Scarselli, Elisa, Cortese, Riccardo, Nicosia, Alfredo, and Cosset, François-Loïc
- Subjects
- *
HEPATITIS C virus , *GLYCOPROTEINS , *CELL membranes - Abstract
Several cell surface molecules have been proposed as receptor candidates, mediating cell entry of hepatitis C virus (HCV) on the basis of their physical association with virions or with soluble HCV E2 glycoproteins. However, due to the lack of infectious HCV particles, evidence that these receptor candidates support infection was missing. Using our recently described infectious HCV pseudotype particles (HCVpp) that display functional E1E2 glycoprotein complexes, here we show that HCV is a pH-dependent virus, implying that its receptor component(s) mediate virion internalization by endocytosis. Expression of the CD81 tetraspanin in non-permissive CD81-negative hepato-carcinoma cells was sufficient to restore susceptibility to HCVpp infection, confirming its critical role as a cell attachment factor. As a cell surface molecule likely to mediate endosomal trafficking, we demonstrate that the human scavenger receptor class B type 1 (SR-B1), a high-density lipoprotein-internalization molecule that we previously proposed as a novel HCV receptor candidate due to its affinity with E2 glycoproteins, is required for infection of CD81-expressing hepatic cells. By receptor competition assays, we found that SR-B1 antibodies that blocked binding of soluble E2 could prevent HCVpp infectivity. Furthermore, we establish that the hyper-variable region 1 of the HCV E2 glycoprotein is a critical determinant mediating entry in SR-B1-positive cells. Finally, by correlating expression of HCV receptors and infectivity, we suggest that, besides CD81 and SR-B1, additional hepatocyte-specific co-factor(s) are necessary for HCV entry. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
43. Binding of the Hepatitis C Virus E3 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2.
- Author
-
Roccasecca, Rosa Maria, Ansuini, Helenia, Vitelli, Alessandra, Meola, Annalisa, Scarselli, Elisa, Acali, Stefano, Pezzanera, Monica, Ercole, Bruno Bruni, McKeating, Jane, Yagnik, Asutosh, Lahm, Armin, Tramontano, Anna, Cortese, Riccardo, and Nicosia, Alfredo
- Subjects
- *
GLYCOPROTEINS , *HYPERVARIABLE regions , *HEPATITIS C virus - Abstract
The envelope glycoprotein E2 of hepatitis C virus (HCV) is the target of neutralizing antibodies and is presently being evaluated as an HCV vaccine candidate. HCV binds to human cells through the interaction of E2 with the tetraspanin CD81, a putative viral receptor component. We have analyzed four different E2 proteins from la and lb viral isolates for their ability to bind to recombinant CD81 in vitro and to the native receptor displayed on the surface of Molt-4 cells. A substantial difference in binding efficiency between these E2 variants was observed, with proteins derived from lb subtypes showing significantly lower binding than the la protein. To elucidate the mechanism of E2-CD81 interaction and to identify critical regions responsible for the different binding efficiencies of the E2 variants, several mutants were generated in E2 protein regions predicted by computer modeling to be exposed on the protein surface. Functional analysis of these E2 derivatives revealed that at least two distinct domains are responsible for interaction with CD81. A first segment centered around amino acid residues 613 to 618 is essential for recognition, while a second element including the two hypervariable regions (HVRs) modulates E2 receptor binding. Binding inhibition experiments with anti-HVR monoclonal antibodies confirmed this mapping and supported the hypothesis that a complex interplay between the two HVRs of E2 is responsible for modulating receptor binding, possibly through intramolecular interactions. Finally, E2 proteins from different isolates displayed a profile of binding to human hepatic cells different from that observed on Molt-4 cells or isolated recombinant CD81, indicating that additional factors are involved in viral recognition by target liver cells. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
44. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
- Author
-
L Silva-Reyes, Elisa Scarselli, Alfredo Nicosia, Stefania Capone, Paul Klenerman, Tamsin Cargill, C de Lara, Andrew J. Pollard, Charles J. Sande, Amber J. Thompson, Kathryn Mary Taylor, Claire Hutchings, Brian Angus, Christopher A Green, Alessandra Vitelli, K Haworth, Green, Christopher A., Sande, Charles J., Scarselli, Elisa, Capone, Stefania, Vitelli, Alessandra, Nicosia, Alfredo, Silva-Reyes, Laura, Thompson, Amber J., de Lara, Catherine M., Taylor, Kathryn S., Haworth, Kathryn, Hutchings, Claire L., Cargill, Tamsin, Angus, Brian, Klenerman, Paul, and Pollard, Andrew J.
- Subjects
Viral vectors ,Male ,0301 basic medicine ,Cellular immunity ,T-Lymphocytes ,viruses ,Respiratory syncytial virus ,Antibodies, Viral ,Elderly ,0302 clinical medicine ,Medicine ,030212 general & internal medicine ,Older adult ,B-Lymphocytes ,Drug Carriers ,Immunity, Cellular ,Vaccines, Synthetic ,Immunogenicity ,ELISPOT ,virus diseases ,Respiratory infection ,respiratory system ,Middle Aged ,Healthy Volunteers ,Vaccination ,Infectious Diseases ,Older adults ,Respiratory syncytial viru ,Female ,Adult ,Microbiology (medical) ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,030106 microbiology ,Vaccinia virus ,Respiratory Syncytial Virus Infections ,Injections, Intramuscular ,Article ,Mastadenovirus ,Young Adult ,03 medical and health sciences ,Viral vector ,Immune system ,Immunity ,Respiratory Syncytial Virus Vaccines ,Humans ,Antibody-Producing Cells ,Administration, Intranasal ,Immunization Schedule ,Aged ,business.industry ,Vaccine trial ,Antibodies, Neutralizing ,Immunity, Humoral ,Respiratory Syncytial Virus, Human ,Immunology ,business ,Vaccine - Abstract
Highlights • There is no licensed vaccine to prevent severe disease caused by respiratory syncytial virus (RSV) infection. • RSV is a major cause of hospitalisation and death in the elderly. • The novel viral-vectored vaccines PanAd3-RSV and MVA-RSV appeared safe and boosted both humoral and cellular RSV-specific immune responses in healthy older adults. • The magnitude of immune responses to vaccination appeared similar to what was observed in younger adults., Objectives Respiratory syncytial virus (RSV) causes respiratory infection across the world, with infants and the elderly at particular risk of developing severe disease and death. The replication-defective chimpanzee adenovirus (PanAd3-RSV) and modified vaccinia virus Ankara (MVA-RSV) vaccines were shown to be safe and immunogenic in young healthy adults. Here we report an extension to this first-in-man vaccine trial to include healthy older adults aged 60–75 years. Methods We evaluated the safety and immunogenicity of a single dose of MVA-RSV given by intra-muscular (IM) injection (n = 6), two doses of IM PanAd3-RSV given 4-weeks apart (n = 6), IM PanAd3-RSV prime and IM MVA-RSV boost 8-weeks later (n = 6), intra-nasal (IN) spray of PanAd3-RSV prime and IM MVA-RSV boost 8-weeks later (n = 6), or no vaccine (n = 6). Safety measures included all adverse events within one week of vaccination and blood monitoring. Immunogenicity measures included serum antibody responses (RSV- and PanAd3-neutralising antibody titres measured by plaque-reduction neutralisation and SEAP assays, respectively), peripheral B-cell immune responses (frequencies of F-specific IgG and IgA antibody secreting cells and memory B-cells by ex vivo and cultured dual-colour ELISpot assays respectively), and peripheral RSV-specific T-cell immune responses (frequencies of IFNγ-producing T-cells by ex vivo ELISpot and CD4+/CD8+/Tfh-like cell frequencies by ICS/FACS assay). Results The vaccines were safe and well tolerated. Compared with each individual baseline immunity the mean fold-changes in serum RSV-neutralising antibody, appearance and magnitude of F-specific IgG and IgA ASCs and expansion of CD4+/CD8+ IFNγ-producing T-cells in peripheral circulation were comparable to the results seen from younger healthy adults who received the same vaccine combination and dose. There were little/no IgA memory B-cell responses in younger and older adults. Expansion of IFNγ-producing T-cells was most marked in older adults following IM prime, with balanced CD4+ and CD8+ T cell responses. The RSV-specific immune responses to vaccination did not appear to be attenuated in the presence of PanAd3 (vector) neutralising antibody. Conclusions PanAd3-RSV and MVA-RSV was safe and immunogenic in older adults and the parallel induction of RSV-specific humoral and cellular immunity merits further assessment in providing protection from severe disease.
- Published
- 2019
45. Longitudinal transcriptomic and genetic landscape of radiotherapy response in canine melanoma
- Author
-
Piero Fariselli, Diana Giannuzzi, Mauro Dacasto, Ramy Elgendy, Mery Giantin, Laura Marconato, Vito F. Leone, Alfredo Nicosia, P Laganga, Sara Pegolo, Guido Leoni, Elisa Scarselli, Serena Ferraresso, Fulvia Troise, Luca Aresu, Giannuzzi D., Marconato L., Elgendy R., Ferraresso S., Scarselli E., Fariselli P., Nicosia A., Pegolo S., Leoni G., Laganga P., Leone V.F., Giantin M., Troise F., Dacasto M., Aresu L., Giannuzzi, Diana, Marconato, Laura, Ramy, Elgendy, Ferraresso, Serena, Scarselli, Elisa, Fariselli, Piero, Nicosia, Alfredo, Pegolo, Sara, Leoni, Guido, Laganga, Paola, Ferdinando, Leone Vito, Giantin, Mery, Troise, Fulvia, Dacasto, Mauro, and Aresu, Luca
- Subjects
Male ,040301 veterinary sciences ,medicine.medical_treatment ,Biology ,radiation therapy ,0403 veterinary science ,Transcriptome ,03 medical and health sciences ,0302 clinical medicine ,Dogs ,medicine ,Canine Melanoma ,melanoma ,Animals ,Dog Diseases ,Exome ,Exome sequencing ,PI3K/AKT/mTOR pathway ,Chromosome Aberrations ,General Veterinary ,Base Sequence ,Melanoma ,Gene Expression Profiling ,Cancer ,04 agricultural and veterinary sciences ,medicine.disease ,Radiation therapy ,Gene Expression Regulation, Neoplastic ,Dog ,RNA-seq ,030220 oncology & carcinogenesis ,Mutation ,dog ,Cancer research ,Female ,exome sequencing - Abstract
Canine malignant melanoma is a highly aggressive tumor with a low survival rate and represents an ideal spontaneous model for the human counterpart. Considerable progress has been recently obtained, but the therapeutic success for canine melanoma is still challenging. Little is known about the mechanisms beyond pathogenesis and melanoma development, and the molecular response to radiotherapy has never been explored before. A faster and deeper understanding of cancer mutational processes and developing mechanisms are now possible through next generation sequencing technologies. In this study, we matched whole exome and transcriptome sequencing in four dogs affected by malignant melanoma at diagnosis and at disease progression to identify possible genetic mechanisms associated with therapy failure. According to previous studies, a genetic similarity between canine malignant melanoma and its human counterpart was observed. Several somatic mutations were functionally related to MAPK, PI3K/AKT and p53 signaling pathways, but located in genes other than BRAF, RAS and KIT. At disease progression, several mutations were related to therapy effects. Natural killer cell-mediated cytotoxicity and several immune-system-related pathways resulted activated opening a new scenario on the microenvironment in this tumor. In conclusion, this study suggests a potential role of the immune system associated to radiotherapy in canine melanoma, but a larger sample size associated with functional studies are needed. This article is protected by copyright. All rights reserved.
- Published
- 2019
46. Chimpanzee adenoviral vectors as vaccines–challenges to move the technology into the fast lane
- Author
-
Stefania Capone, Antonella Folgori, Alfredo Nicosia, Alessandra Vitelli, Stefano Colloca, Elisa Scarselli, Vitelli, Alessandra, Folgori, Antonella, Scarselli, Elisa, Colloca, Stefano, Capone, Stefania, and Nicosia, Alfredo
- Subjects
0301 basic medicine ,Pan troglodytes ,Genetic Vectors ,Immunology ,Drug Evaluation, Preclinical ,Chimpanzee adenovirus ,Biology ,Viral vector ,Adenoviridae ,03 medical and health sciences ,0302 clinical medicine ,T-cell ,Immunity ,Drug Discovery ,Animals ,Humans ,Technology, Pharmaceutical ,Mucosal immunity ,Drug Carrier ,Pharmacology ,Drug Carriers ,Vaccines ,Clinical Trials as Topic ,Animal ,Drug Discovery3003 Pharmaceutical Science ,viral vector ,Pan troglodyte ,Virology ,chimpanzee adenoviru ,immunity ,030104 developmental biology ,030220 oncology & carcinogenesis ,mucosal immunity ,Molecular Medicine ,Genetic Vector ,Vaccine ,Human - Abstract
In recent years, replication-defective chimpanzee-derived adenoviruses have been extensively evaluated as genetic vaccines. These vectors share desirable properties with human adenoviruses like the broad tissue tropism and the ease of large-scale manufacturing. Additionally, chimpanzee adenoviruses have the advantage to overcome the negative impact of pre-existing anti-human adenovirus immunity. Areas covered: Here the authors review current pre-clinical research and clinical trials that utilize chimpanzee-derived adenoviral vectors as vaccines. A wealth of studies are ongoing to evaluate different vector backbones and administration routes with the aim of improving immune responses. The challenges associated with the identification of an optimal chimpanzee vector and immunization strategies for different immunological outcomes will be discussed. Expert commentary: The demonstration that chimpanzee adenoviruses can be safely used in humans has paved the way to the use of a whole new array of vectors of different serotypes. However, so far no predictive signature of vector immunity in humans has been identified. The high magnitude of T cell responses elicited by chimpanzee adenoviruses has allowed dissecting the qualitative aspects that may be important for protective immunity. Ultimately, only the results from the most clinically advanced products will help establish the efficacy of the vaccine vector platform in the field of disease prevention.
- Published
- 2017
47. New viral vectors for infectious diseases and cancer.
- Author
-
Sasso, Emanuele, D'Alise, Anna Morena, Zambrano, Nicola, Scarselli, Elisa, Folgori, Antonella, and Nicosia, Alfredo
- Subjects
- *
GENETIC vectors , *COMMUNICABLE diseases , *DISEASE vectors , *DNA vaccines , *ADENOVIRUS diseases , *EMERGING infectious diseases , *LYMPHOCYTIC choriomeningitis virus - Abstract
• Viral vectored vaccines against infectious diseases: clinical and immunological data. • Use of viral vectors for heterologous prime/boost regimens. • Viral vectors as a tool for vaccine preparedness. • Renaissance of cancer vaccines and the use of viral vectors. • Oncolytic viruses as 'endovaccines'. Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into the current approaches of viral vectored genetic vaccines. In recent years, key improvements to the vaccinia virus leading to a safer version (Modified Vaccinia Ankara, MVA) and the discovery that some viruses can be used as carriers of heterologous genes encoding for pathological antigens of other infectious agents (the concept of 'viral vectors') has spurred a new wave of clinical research potentially providing for a solution for the long sought after vaccines against major diseases such as HIV, TB, RSV and Malaria, or emerging infectious diseases including those caused by filoviruses and coronaviruses. The unique ability of some of these viral vectors to stimulate the cellular arm of the immune response and, most importantly, T lymphocytes with cell killing activity, has also reawakened the interest toward developing therapeutic vaccines against chronic infectious diseases and cancer. To this end, existing vectors such as those based on Adenoviruses have been improved in immunogenicity and efficacy. Along the same line, new vectors that exploit viruses such as Vesicular Stomatitis Virus (VSV), Measles Virus (MV), Lymphocytic choriomeningitis virus (LCMV), cytomegalovirus (CMV), and Herpes Simplex Virus (HSV), have emerged. Furthermore, technological progress toward modifying their genome to render some of these vectors incompetent for replication has increased confidence toward their use in infant and elderly populations. Lastly, their production process being the same for every product has made viral vectored vaccines the technology of choice for rapid development of vaccines against emerging diseases and for 'personalised' cancer vaccines where there is an absolute need to reduce time to the patient from months to weeks or days. Here we review the recent developments in viral vector technologies, focusing on novel vectors based on primate derived Adenoviruses and Poxviruses, Rhabdoviruses, Paramixoviruses, Arenaviruses and Herpesviruses. We describe the rationale for, immunologic mechanisms involved in, and design of viral vectored gene vaccines under development and discuss the potential utility of these novel genetic vaccine approaches in eliciting protection against infectious diseases and cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
48. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults
- Author
-
K Haworth, Stefano Colloca, Elisa Scarselli, Paul Klenerman, C de Lara, Stefania Capone, Loredana Siani, Cinzia Traboni, Alfredo Nicosia, M Del Sorbo, Riccardo Cortese, Alessandra Vitelli, Kathryn Mary Taylor, Antonella Folgori, A J Thompson, Christopher A Green, Charles J. Sande, S Di Marco, Brian Angus, Andrew J. Pollard, Green, Christopher A., Scarselli, Elisa, Sande, Charles J., Thompson, Amber J., De Lara, Catherine M., Taylor, Kathryn S., Haworth, Kathryn, Del Sorbo, Mariarosaria, Angus, Brian, Siani, Loredana, Di Marco, Stefania, Traboni, Cinzia, Folgori, Antonella, Colloca, Stefano, Capone, Stefania, Vitelli, Alessandra, Cortese, Riccardo, Klenerman, Paul, Nicosia, Alfredo, and Pollard, Andrew J.
- Subjects
CD4-Positive T-Lymphocytes ,viruses ,CD8-Positive T-Lymphocytes ,Antibodies, Viral ,Body Temperature ,chemistry.chemical_compound ,0302 clinical medicine ,HEK293 Cell ,030212 general & internal medicine ,0303 health sciences ,Immunogenicity ,Medicine (all) ,Pan troglodyte ,Vaccination ,virus diseases ,Respiratory infection ,General Medicine ,T helper cell ,respiratory system ,Healthy Volunteer ,Healthy Volunteers ,3. Good health ,Respiratory Syncytial Viruses ,medicine.anatomical_structure ,Editorial ,CD4-Positive T-Lymphocyte ,Respiratory Syncytial Virus Vaccine ,Genetic Vector ,Respiratory Syncytial Viruse ,Human ,Adult ,Pan troglodytes ,Genetic Vectors ,Dose-Response Relationship, Immunologic ,Immunization, Secondary ,Vaccinia virus ,Respiratory Syncytial Virus Infections ,Biology ,complex mixtures ,Article ,Virus ,Viral vector ,03 medical and health sciences ,Interferon-gamma ,medicine ,Respiratory Syncytial Virus Vaccines ,Animals ,Humans ,030304 developmental biology ,Respiratory Syncytial Virus Infection ,Animal ,CD8-Positive T-Lymphocyte ,Virology ,Antibodies, Neutralizing ,Vaccinia viru ,HEK293 Cells ,chemistry ,Immunology ,Adenoviruses, Simian ,Vaccinia - Abstract
Respiratory syncytial virus (RSV) causes respiratory infection in annual epidemics, with infants and the elderly at particular risk of developing severe disease and death. However, despite its importance, no vaccine exists. The chimpanzee adenovirus, PanAd3-RSV, and modified vaccinia virus Ankara, MVA-RSV, are replication-defective viral vectors encoding the RSV fusion (F), nucleocapsid (N), and matrix (M2-1) proteins for the induction of humoral and cellular responses. We performed an open-label, dose escalation, phase 1 clinical trial in 42 healthy adults in which four different combinations of prime/boost vaccinations were investigated for safety and immunogenicity, including both intramuscular (IM) and intranasal (IN) administration of the adenovirus-vectored vaccine. The vaccines were safe and well tolerated, with the most common reported adverse events being mild injection site reactions. No vaccine-related serious adverse events occurred. RSV neutralizing antibody titers rose in response to IM prime with PanAd3-RSV and after IM boost for individuals primed by the IN route. Circulating anti-F immunoglobulin G (IgG) and IgA antibody-secreting cells (ASCs) were observed after the IM prime and IM boost. RSV-specific T cell responses were increased after the IM PanAd3-RSV prime and were most efficiently boosted by IM MVA-RSV. Interferon-γ (IFN-γ) secretion after boost was from both CD4(+) and CD8(+) T cells, without detectable T helper cell 2 (TH2) cytokines that have been previously associated with immune pathogenesis following exposure to RSV after the formalin-inactivated RSV vaccine. In conclusion, PanAd3-RSV and MVA-RSV are safe and immunogenic in healthy adults. These vaccine candidates warrant further clinical evaluation of efficacy to assess their potential to reduce the burden of RSV disease.
- Published
- 2016
49. Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates
- Author
-
Angiolo Pierantoni1, Maria Luisa Esposito1, Virginia Ammendola1, Federico Napolitano1, Fabiana Grazioli1, Adele Abbate1, Mariarosaria del Sorbo1, Loredana Siani1, Anna Morena D'Alise1, Alessandra Taglioni3, Gemma Perretta3, Antonio Siccardi4, Elisa Soprana4, Maddalena Panigada4, Michelle Thom2, Elisa Scarselli1, Antonella Folgori1, Stefano Colloca1, Geraldine Taylor2, Riccardo Cortese1, 7, Alfredo Nicosia1, 5, 6, Stefania Capone1, Alessandra Vitelli1, Pierantoni, Angiolo, Esposito, Maria Luisa, Ammendola, Virginia, Napolitano, Federico, Grazioli, Fabiana, Abbate, Adele, del Sorbo, Mariarosaria, Siani, Loredana, D'Alise, Anna Morena, Taglioni, Alessandra, Perretta, Gemma, Siccardi, Antonio, Soprana, Elisa, Panigada, Maddalena, Thom, Michelle, Scarselli, Elisa, Folgori, Antonella, Colloca, Stefano, Taylor, Geraldine, Cortese, Riccardo, Nicosia, Alfredo, Capone, Stefania, and Vitelli, Alessandra
- Subjects
Cellular immunity ,Modified vaccinia Ankara ,lcsh:QH426-470 ,viruses ,Virus ,Article ,Lower respiratory tract infection ,medicine ,Genetics ,lcsh:QH573-671 ,Neutralizing antibody ,Molecular Biology ,biology ,business.industry ,lcsh:Cytology ,Immunogenicity ,virus diseases ,respiratory system ,medicine.disease ,Virology ,3. Good health ,Vaccination ,lcsh:Genetics ,medicine.anatomical_structure ,Immunology ,biology.protein ,Molecular Medicine ,business ,Respiratory tract - Abstract
Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory disease in infants and the elderly. No vaccine is presently available to address this major unmet medical need. We generated a new genetic vaccine based on chimpanzee Adenovirus (PanAd3-RSV) and Modified Vaccinia Ankara RSV (MVA-RSV) encoding the F, N, and M2-1 proteins of RSV, for the induction of neutralizing antibodies and broad cellular immunity. Because RSV infection is restricted to the respiratory tract, we compared intranasal (IN) and intramuscular (M) administration for safety, immunogenicity, and efficacy in different species. A single IN or IM vaccination completely protected BALB/c mice and cotton rats against RSV replication in the lungs. However, only IN administration could prevent infection in the upper respiratory tract. IM vaccination with MVA-RSV also protected cotton rats from lower respiratory tract infection in the absence of detectable neutralizing antibodies. Heterologous prime boost with PanAd3-RSV and MVA-RSV elicited high neutralizing antibody titers and broad T-cell responses in nonhuman primates. In addition, animals primed in the nose developed mucosal IgA against the F protein. In conclusion, we have shown that our vectored RSV vaccine induces potent cellular and humoral responses in a primate model, providing strong support for clinical testing.
- Published
- 2015
50. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
- Author
-
D'Alise AM, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, Garzia I, Antonucci L, Micarelli E, Venafra V, Gogov S, Capone A, Runswick S, Martin-Liberal J, Calvo E, Moreno V, Symeonides SN, Scarselli E, and Bechter O
- Subjects
- Humans, Female, Middle Aged, Male, Melanoma therapy, Melanoma immunology, Aged, Vaccination methods, T-Lymphocytes immunology, Adult, CD8-Positive T-Lymphocytes immunology, Cancer Vaccines immunology, Cancer Vaccines administration & dosage, Antigens, Neoplasm immunology, Antigens, Neoplasm genetics, Genetic Vectors genetics, Genetic Vectors administration & dosage, Precision Medicine methods, Adenoviridae genetics, Adenoviridae immunology
- Abstract
Purpose: Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity. NOUS-PEV is a vector-based personalized vaccine, expressing 60 nAgs and consists of priming with a nonhuman Great Ape Adenoviral vector (GAd20) followed by boosts with Modified Vaccinia Ankara. Here, we report data of a phase Ib trial of NOUS-PEV in combination with pembrolizumab in treatment-naïve patients with metastatic melanoma (NCT04990479)., Patients and Methods: The feasibility of this approach was demonstrated by producing, releasing, and administering to 6 patients 11 of 12 vaccines within 8 weeks from biopsy collection to GAd20 administration., Results: The regimen was safe, with no treatment-related serious adverse events observed and mild vaccine-related reactions. Vaccine immunogenicity was demonstrated in all evaluable patients receiving the prime/boost regimen, with detection of robust neoantigen-specific immune responses to multiple neoantigens comprising both CD4 and CD8 T cells. Expansion and diversification of vaccine-induced T-cell receptor (TCR) clonotypes was observed in the posttreatment biopsies of patients with clinical response, providing evidence of tumor infiltration by vaccine-induced neoantigen-specific T cells., Conclusions: These findings indicate the ability of NOUS-PEV to amplify and broaden the repertoire of tumor-reactive T cells to empower a diverse, potent, and durable antitumor immune response. Finally, a gene signature indicative of the reduced presence of activated T cells together with very poor expression of the antigen-processing machinery genes has been identified in pretreatment biopsies as a potential biomarker of resistance to the treatment., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.